Healthy Subjects Clinical Trial
Official title:
Identification of Physiological and Behavioural Biomarkers to Predict Take-over Control Quality in Level 3 Conditionally Automated Vehicles
At level 3 conditionally automated, the vehicle ensures driving and the driver disengages
from driving to perform another activity independent of driving (ex: read a book, play on his
phone ....). However, drivers are expected to be available to take over control for the case
of system failure or limitation. This take-over control must take place in a limited time,
very short, of the order of a few seconds. To take-over control of the vehicle quickly and
efficiently, the driver must be, at the time of take-over, vigilant, efficient, and attentive
to the environment and focused on the take-over of manual driving. Predicting the driver's
reengagement capabilities to ensure that the driver will be able to take-over control of the
vehicle is crucial at level 3 of autonomous driving.
The objective of ANTIDOTE is to determine physiological and behavioural parameters capable of
predicting the take-over quality in level 3 conditionally automated vehicles in a simulated
highway driving situation in healthy drivers or drivers with attention disorders.
At level 3 conditionally automated, the vehicle ensures driving and the driver disengages
from driving to perform non-related driving tasks (ex: read a book, play on his phone ....).
However, drivers are expected to be available to take over control for the case of system
failure or limitation. This take-over control must take place in a limited time, very short,
of the order of a few seconds. To take-over control of the vehicle quickly and efficiently,
the driver must be, at the time of take-over, vigilant, efficient, and attentive to the
environment and focused on the take-over of manual driving. Predicting the driver's
reengagement capabilities to ensure that the driver will be able to take-over control of the
vehicle is crucial at level 3 of autonomous driving.
In this context, the objective of ANTIDOTE is to determine physiological and behavioural
parameters capable of predicting the take-over quality in level 3 conditionally automated
vehicles in a simulated highway driving situation.
This study will examine how engagement will impact take-over control quality in 6 non-driving
related secondary tasks. A driving simulator study will be conducted and data from a total of
32 healthy drivers and 16 drivers with attention disorders will be used to evaluate take-over
quality.
Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioral data will be recorded
before, during and after the take-over control.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
| Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
| Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
| Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
| Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
| Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
| Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
| Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
| Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
| Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
| Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
| Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
| Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
| Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
| Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
| Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |